Lauren Martin

Lauren Martin is a patent litigation attorney with Quinn Emanuel Urquhart & Sullivan, LLP, based in their Boston office, where she was elected partner in January 2024. Her practice focuses on complex patent disputes, particularly within the biotechnology, medical device, diagnostic testing, and chemical arts sectors.

Martin's experience spans both plaintiff and defendant representation, though her tracked appearances show a preference for plaintiff-side work with six plaintiff and two defendant roles across eight cases. She has served in various capacities, including Lead Counsel, Of Counsel, and Senior Counsel, demonstrating her comprehensive involvement in all aspects of litigation, from strategy development and discovery to trial and appeals.

She has been involved in several high-profile pharmaceutical patent litigations. Representing defendant Samsung Bioepis Co., Ltd. against Regeneron Pharmaceuticals, Inc., she was counsel in a case where the Federal Circuit affirmed a preliminary injunction concerning an EYLEA® biosimilar. As senior counsel for defendant Celltrion, Inc. in another Regeneron EYLEA® biosimilar dispute, the case was dismissed without prejudice by joint stipulation, allowing Celltrion to launch its biosimilar in late 2026. On the plaintiff side, Martin represented Halozyme, Inc. in its litigation against Merck Sharp & Dohme Corp. over Merck's subcutaneous KEYTRUDA® formulation, securing a preliminary injunction in Germany and navigating ongoing U.S. district court proceedings where Halozyme alleges infringement of 15 MDASE™ technology patents. Notably, a Halozyme patent related to this dispute was recently invalidated by the PTAB. Her notable successes also include representing C.R. Bard in a patent infringement litigation where a jury found in their favor on all issues, and securing favorable settlements after trial victories for Vifor Fresenius in Hatch-Waxman cases.

Martin also possesses experience in Patent Trial and Appeal Board (PTAB) proceedings, having represented Halozyme, Inc. as a patent owner facing numerous Post-Grant Reviews (PGRs) and Inter Partes Reviews (IPRs) initiated by Merck, and her work on the Halozyme v. Merck litigation involved a PTAB final written decision. She earned her J.D. from The University of Chicago Law School in 2010 and has been licensed to practice in Massachusetts since 2014.